Advertisement

Einsatz und Wirkung von Medikamenten

Chapter
  • 1k Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

4.4 Literatur

  1. Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101: 1206–1218PubMedGoogle Scholar
  2. Bräunlich S, Kröger K, Masssalha K, Rudofsky G (1999) Ergotamin-induced intermittent claudication. VASA 28: 123–126CrossRefPubMedGoogle Scholar
  3. CAPRIE Steering Commitee (1996) A randomized, blinded trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339Google Scholar
  4. Claus G, Gulba DC (1993) Unerwünschte Begleitwirkungen der Thrombolysetherapie. Innere Med 48: 296–303Google Scholar
  5. Cole MS, Minifee PK, Wolma FJ (1988) Coumarin necrosis — a review of the literature. Surgery 103: 271–277PubMedGoogle Scholar
  6. Columbus Investigators (1997) Low molecular-weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. N Engl J Med 337: 657–662Google Scholar
  7. Couch NP (1989) About heparin. Whatever happened to Jay McLean? J Vasc Surg 10: 1–8CrossRefPubMedGoogle Scholar
  8. Greinacher A (1996) Heparin-induzierte Thrombozytopenien. Internist 37: 1172–1178PubMedGoogle Scholar
  9. Greenfield LJ (1988) Coumarin: friend and foe. Surgery 103: 386–387PubMedGoogle Scholar
  10. Harenberg J (1981) Metabolismus von Heparin. Nie-ren Hochdruckkrankh 10: 101–105Google Scholar
  11. Harenberg J, Fenyvesi T (2004) Heparine, Thrombin-und Faktor-Xa-Inhibitoren. Hämostaseologie 24: 261–278PubMedGoogle Scholar
  12. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353: 307–314PubMedGoogle Scholar
  13. Hirsh J (1991) Heparin. N Engl J Med 324: 1565–1574PubMedGoogle Scholar
  14. Hirsh J, Weitz JI (1999) New antithrombotic agents. Lancet 353: 1431–1436PubMedGoogle Scholar
  15. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H (1995) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (Suppl) 108: 231S–246SPubMedGoogle Scholar
  16. Jaques LB (1940) Heparinase. J Biol Chem 133: 445–451Google Scholar
  17. Kappa JR, Fisher CA, Addonizio VP (1989) Heparin-induced platelet activation: the role of thromboxane A2 synthesis and the extent of platelet granule release in two patients. J Vasc Surg 9: 574–579CrossRefPubMedGoogle Scholar
  18. Kemkes-Matthes B, Barthels M (2004) Orale Antikoagulanzien vom Cumarintyp. Hämostaseologie 24: 279–285PubMedGoogle Scholar
  19. Kleinschmidt S, Seyfert UT (1999) Die Heparin-induzierte Thrombozytopenie (HIT). Bedeutung fur Anästhesie und Intensivmedizin. Anaesthesist 48:771–785CrossRefPubMedGoogle Scholar
  20. Lane DA, Lindahl U (1989) Heparin — chemical and biological properties, clinical applications. Arnold, LondonGoogle Scholar
  21. Laster J, Elfrink R, Silver D (1989) Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg 9: 677–682CrossRefPubMedGoogle Scholar
  22. Matis P, Mayer W (1979) Zur Geschichte der „klassischen” Antikoagulantien Heparin und Dicumarol. Med Welt 30: 845–848PubMedGoogle Scholar
  23. Mehta SR, Yusuf S, Peters RJG (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE Study. Lancet 358: 527–533PubMedGoogle Scholar
  24. Ranke C, Creutzig A, Alexander K (1994) Acetylsalicylsäure bei arteriellen Durchblutungsstörungen. Dtsch Med Wochenschr 119: 815–821PubMedGoogle Scholar
  25. Ranze O, Greinacher A (1999) Danaparoid-Natrium: Antikoagulation bei Heparin-induzierter Thrombozytopenie. Arzneimitteltherapie 17: 354–358Google Scholar
  26. Rauber K (1993) Thrombolytische Therapie arterieller Verschlüsse. Innere Med 48: 344–350Google Scholar
  27. Sternbergh WC, Makhoul RG, Adelman B (1993) Heparin prevents postischemic endothelial cell dysfunction by a mechanism independent of its anticoagulant activity. J Vasc Surg 17: 318–327PubMedGoogle Scholar
  28. Stille S (2000) Antibiotika-Therapie in Klinik und Praxis, 10. Aufl. Schattauer, Stuttgart New YorkGoogle Scholar
  29. Theuretzbacher U (2004) Mikrobiologie im klinischen Alltag. Kohlhammer, StuttgartGoogle Scholar
  30. Tobelem G (1989) Endothelial cell interactions with heparin. Semin Thromb Hemostasis 15: 197–199Google Scholar
  31. Vogel F et al (1999) Parenterale Antibiotika bei Erwachsenen (Expertenkommission der Paul-Ehrlich-Gesellschaft). Chemotherapie 8Google Scholar
  32. Winter J, Ludwig M (1995) Sekundärprophylaktische Dosierung des Thrombozytenaggregationshemmers ASS bei peripherer arterieller Verschlusskrankheit: Was ist gesichert? Herz Kreislauf 27: 106–112Google Scholar
  33. Wolfram S, Jensen KS, Liao JK (2003) Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23: 729–736Google Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Personalised recommendations